Conference Day Two | Thursday, March 13 2025

8:10 am Coffee & Registration

8:25 am Chair’s Opening Remarks

  • Chris Baldwin Vice President, Manufacturing & Supply, Resolution Therapeutics

Establishing Effective Cross-Collaboration Between Supply Chain Stakeholders

8:30 am Implementing Integrated Digital Solutions into Supply Chains

Synopsis

  • How and when should I digitalize?
  • Finding phase- and stage- appropriate solutions that encompass both product and patient journeys
  • Co-ordinating system choice and implementation with what’s best for the hospital site

9:00 am IWG Risk-Based Center Qualification & Autolus’ Implementation

Synopsis

  • Outline of the IWG risk-based center qualification process
  • Benefits to Treatment Centers and Industry
  • Autolus case-study: implementation in the real-world

9:30 am Mastering the CDMO Selection, Negotiation & Relationship Building Process

  • Ute Brassat Director - Cell Therapy & Manufacturing, T-Knife Therapeutics

Synopsis

  • Designing an efficient evaluation process
  • Ensuring that the CDMO has the required capabilities
  • Negotiating terms and costs for tech transfer and clinical batch manufacturing

10:30 am Morning Refreshments & Speed Networking

10:40 am Cell Therapy Patient Operations: Creating a Positive Customer Experience

  • Michael Mehler Director, Head of Cell Therapy Patient Operations, AstraZeneca

Synopsis

  • How can a Patient Operations role support cell therapy sites, and why is it critical to provide this level of support to sites?
  • With multiple teams touching the cell therapy vein-to-vein process, it is critical that manufacturers provide support from apheresis to infusion
  • A Cell Therapy Patient Operations team provides white glove service that differentiates from other manufacturers

11:10 am Panel Discussion: Simplifying Processes Between Different Partners to Create an Integrated Supply Chain

  • Jie Jia Vice President, Strategic Alliances & Operations, CARsgen Therapeutics
  • Kevin Liao Director, Supply Chain, Caribou Biosciences
  • Albert Ribickas Manager, Blood & Marrow Transplant Laboratory, Moffitt Cancer Center

Synopsis

  • How to work with partners to deliver full-service levels during unpredictable demand and constrained capacity
  • Considerations for ensuring partners implement new technology systems
  • Simplification of clinical activities to make logistics work in practice

Developing & Implementing Industry Standards

11:50 am Overcoming Interoperability Challenges through Standardization

Synopsis

  • Describing problem areas that hinder full traceability of medical products of human origin (MPHO)
  • Discussing HL7® FHIR® and USCDI standards
  • Expanding interoperability solutions to enhance MPHO traceability

12:20 pm Lunch & Networking

1:20 pm Differences in Apheresis Collection Requirements Between Different CAR-T Cell Manufacturers

  • Aleh (Oleg) Bobr Director of Blood Bank & Tissue Service; Associate Director for Apheresis, University of Nebraska Medical Center

Synopsis

  • Describing the mechanism and general approach for mononuclear cells collections by apheresis
  • Presenting current differences in collection protocols required by manufacturers
  • Proposing possible solutions to deal with the current situation and ways to achieve industry-wide standardization

1:50 pm Audience Discussion: Brainstorming Solutions to the Lack of Industry Standardization

  • Aleh (Oleg) Bobr Director of Blood Bank & Tissue Service; Associate Director for Apheresis, University of Nebraska Medical Center
  • Karen Moniz Technical Director, ICCBBA

Synopsis

  • Across drug sponsors, hospitals and vendors – where are standardized protocols most in need of defining and implementing?
  • Generating actionable ideas to standardise packaging, labelling, shipping, and collection requirements for CGTs
  • How could these be implemented tomorrow to secure a faster end-to-end supply chain?

2:45 pm Afternoon Refreshments & Networking

Navigating Different Requirements & Ensuring Global Compliance

3:15 pm Considerations for Raw Material Selection and Testing to Support a Commercial Product

Synopsis

  • Understanding the nuances of defining raw materials as ancillary or excipient
  • Clarifying USP, EP, BP and JP raw material grade requirements: what grade of material should I be selecting?
  • Ensuring security of supply and quality of materials for CGTs

3:45 pm Panel Discussion: Highlighting Key Differences in Global Supply Chain Regulations Between Different Bodies

Synopsis

  • What are some key US vs EU regional differences that impact critical and/or raw material sourcing, and supply chain continuity for drug sponsors?
  • How do expectations and benchmarks differ between the FDA and EMA?
  • Practical advice for CGT developers working in both regions

4:25 pm Chair’s Closing Remarks

  • Chris Baldwin Vice President, Manufacturing & Supply, Resolution Therapeutics

4:30 pm End of 6th Supply Chain & Logistics for Cell & Gene Therapies Summit